PAI Partners (PAI), a leading private equity firm, is set to acquire a 67% majority stake in the European rehabilitation unit of Vamed, a subsidiary of the healthcare giant Fresenius SE & Co. KGaA. This transaction, leveraging PAI’s Mid-Market Fund, will result in a strategic partnership with Fresenius retaining a 33% share. Vamed’s rehabilitation business is a top-tier service provider in Europe, managing 67 centers and catering to over 100,000 patients per year. With approximately 10,000 dedicated staff, the company offers a suite of inpatient and outpatient services, specializing in various medical domains such as neurology and cardiology. PAI aims to harness its healthcare industry prowess and carve-out experience—demonstrated by previous investments like DomusVi and a joint venture with Nestl—to elevate Vamed’s operations and patient services.

The deal is poised to empower the rehabilitation unit to achieve operational excellence and expand its talent pool, fostering even greater dedication to patient care. Slated to close in the second half of 2024, pending regulatory and other standard conditions, the move marks PAI’s 20th carve-out. PAI will leverage this acquisition to bolster its presence in healthcare, drawing on a synergistic partnership that harnesses shared expertise for the enhancement of medical outcomes. The transaction awaits approval from a Vamed General Meeting, where Fresenius, with a 77% majority, anticipates swift affirmation. The deal announcement also serves as a testament to PAI’s strategy of collaborating with driven management teams, allowing businesses to truly realize their potential and reach new heights of performance.

Private Equity, Healthcare Services,Europe

PAI Partners to acquire majority stake in Vamed’s European rehabilitation business